Former CEO Peter Greenleaf files intent to sell $49.7M in shares
AUPH has more than doubled off its 52-week low of $7.285 on elevated volume (1.9× avg).
Summary
Former CEO Peter Greenleaf intends to sell $49.7 million in Aurinia Pharmaceuticals shares, a significant transaction following recent leadership changes.
Key Events · Ownership and Investor Activity · AUPH
-
Intent to Sell Shares
Peter Greenleaf, a former affiliate (previously CEO), filed a Form 144 to sell 3,136,201 common shares.
-
Significant Transaction Value
The proposed sale has an approximate market value of $49,677,423.84, representing about 2.44% of the company's outstanding shares.
-
Cashless Option Exercise
The sale is described as a cashless exercise of options and subsequent sale, often for liquidity or tax planning.
-
Follows Leadership Transition
This filing by the former CEO follows a recent executive leadership overhaul where Kevin Tang was appointed CEO on March 23, 2026.
Analysis · AUPH · Life Sciences
Former CEO Peter Greenleaf has filed a Form 144 indicating his intent to sell approximately $49.7 million worth of shares, representing about 2.46% of the company's outstanding shares. This sale is described as a cashless exercise of options and subsequent sale. While often pre-planned for liquidity or tax purposes, the substantial size of this transaction from a former executive is notable, especially following the recent executive leadership overhaul where Kevin Tang took over as CEO.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AUPH was trading at $15.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $7.29 to $16.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.